In order to determine if the morphological changes induced by cisplatin and paclitaxel were consistent with the chemoresistant phenotype of the ovarian tumors as described previously [25,26], we evaluated the expression of ERCC1 and β-tubulin isotype III by cancer cells which survived cisplatin, paclitaxel and combination treatments using immunofluorescence. The gene discussed is ERCC1; the disease is cancer.